KCT0003813尚未招募未知
A Randomized and Open-label Study to Compare Efficacy and Safety after Switching from Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Adult (male and female) subjects above 20
- •2. Diagnosed as chronic hepatitis B
- •3. Patients treated with TDF monotherapy or TDF-based combination therapy, or those who converted to TAF within 4 weeks prior to screening during TDF treatment for antiviral-resistance
- •4. Patients who want voluntary participation in this study
排除标准
- •Co-infection with HIV or HCV
研究者
相似试验
撤回
2 期
A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin with Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjectsflu1002146010047438influenzaNL-OMON32856PRA International EDS56
进行中（未招募）
不适用
A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin with Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects - TCAD Therapy for treatment of influenza A in immunocompromised subjectsInfluenza A VirusEUCTR2009-015850-39-NLAdamas Pharmaceuticals, Inc250
终止
2 期
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised SubjectsInfluenza AACTRN12609000708257Adamas Pharmaceuticals, Inc125
进行中（未招募）
1 期
Randomized not blinded clinical trial to compare two sequences oftreatment: STZ-5FU followed by everolimus or everolimus followed by STZ-5FU upon progression in advanced progressive pancreatic neuroendocrinetumors (SEQTOR study)advanced progressive pNETsMedDRA version: 17.1Level: PTClassification code 10067517Term: Pancreatic neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000726-66-FRGrupo Español de Tumores Neuroendocrinos (GETNE)180
进行中（未招募）
1 期
Randomized open label study to compare the efficacy and safetyof everolimus followed by chemotherapy with STZ-5FU upon progression orthe reverse sequence, chemotherapy with STZ-5FU followed by everolimusupon progression, in advanced progressive pNETs(SEQTOR study)advanced progressive pNETsMedDRA version: 20.1Level: PTClassification code 10067517Term: Pancreatic neuroendocrine tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000726-66-DKGrupo Español de Tumores Neuroendocrinos (GETNE)140